EDGAR·FLOW

Pelthos Therapeutics Inc. — Form 8-K

Filed November 12, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 78/100
What the filing says
Pelthos announced Q3 2026 net product revenue of $15.2M (up 114% from $7.1M in Q3 2025), with 12,384 Zelsuvmi units dispensed and formulary coverage reaching 127M commercially covered lives. On October 30, 2026, Pelthos entered a definitive merger agreement with Castle Creek Biosciences (late-stage gene therapy company with lead candidate D-Fi for dystrophic epidermolysis bullosa), expected to close by end of Q1 2027. Pelthos also drew an additional $10.0M from Horizon Technology Finance (on top of $30M previously drawn), bringing total debt to $40M under a $50M facility, with $10M more available if trailing twelve-month revenue reaches $70M by December 2027.
Why this rating

Castle Creek merger is transformative for $6.7M market-cap company, adding gene therapy platform. Zelsuvmi strong revenue growth and debt financing substantial relative to size, but merger execution risk and negative stockholders' equity ($6.2M deficit) are concerns.

Tradability signal
NO TRADE

No trade: positive news with only +0.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.33% over 4 hrs, n=451). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$9.39
+10 min · unknown
$9.27 ▼ 1.33%
+30 min · unknown
$9.01 ▼ 4.10%
+1 hr · unknown
$9.23 ▼ 1.65%
+4 hrs · unknown
$8.13 ▼ 13.37%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ PTHS · stock on Yahoo Finance ↗

See more from November 12, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.